Verona_Pharma_Dark_medium.jpg
Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China
June 10, 2021 02:00 ET | Verona Pharma plc
$40 million upfront including $25 million cash and $15 million in equity in Nuance Biotech (parent company) Up to $179 million in potential clinical, regulatory, and commercial milestone payments...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Present at Jefferies Virtual Healthcare Conference
May 25, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona.jpg
Verona Pharma to Present Expanded Analysis of Phase 2b COPD Data with Ensifentrine at the American Thoracic Society 2021 International Conference
May 04, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., May 04, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona.jpg
Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update
April 29, 2021 02:00 ET | Verona Pharma plc
ENHANCE Phase 3 program enrollment continues on track to complete in 2H21 Board strengthened with NED appointment of Lisa Deschamps Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and...
Verona.jpg
Verona Pharma Announces Publication of Phase 2b Dose-Ranging COPD Data in the International Journal of Chronic Obstructive Pulmonary Disease
April 27, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., April 27, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona.jpg
Verona Pharma Reports Results of Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19
April 23, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., April 23, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona.jpg
Verona Pharma to Report First Quarter 2021 Financial Results and Provide Corporate Update
April 21, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., April 21, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona.jpg
Lisa Deschamps Joins Verona Pharma as Non-Executive Director
March 02, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,...
Verona.jpg
Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference
March 01, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona.jpg
Verona Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
February 25, 2021 02:00 ET | Verona Pharma plc
Positive Phase 2 results with pMDI ensifentrine in COPD Enrollment ongoing in ENHANCE Phase 3 program  Up to $30 million debt finance facility increases financial flexibility Conference...